EU Approves First Oral IL-23 Inhibitor Pill for Psoriasis Treatment

The European Union has granted marketing authorization for a new oral medication named Icotyde (active ingredient: icotrokinra), developed by Johnson & Johnson, offering a targeted daily pill treatment for moderate-to-severe psoriasis without the need for injections.

A Breakthrough in Psoriasis Treatment

Psoriasis is a chronic inflammatory skin disease characterized by red lesions covered with scales, often accompanied by itching, pain, and a significant impact on quality of life. The new drug works through targeted blocking of the IL-23 protein receptor, which plays a central role in the inflammatory process causing psoriasis lesions. It represents the first approved oral therapy targeting the IL-23 pathway directly, whereas previous treatments targeting this pathway were administered exclusively via injections.

"The new oral treatment offers patients a more convenient targeted therapy option, although it is not necessarily suitable for all patients and does not replace all existing treatments."

Clinical Trials and Safety Profile

The approval was based on four Phase III clinical studies involving approximately 2,500 adults and adolescents aged 12 and older weighing at least 40 kilograms. The data demonstrated significant skin improvement within roughly four months. However, the medication is not risk-free; the European Medicines Agency reported that the most common side effect was fungal infections, occurring in about 1.1% of patients. Pre-treatment evaluations, including tuberculosis screening and vaccination status assessments, are required due to the drug's impact on the immune system.

Availability and Future Outlook

Following its approval by the US FDA last March and now by the European Union, the official launch date in other regions remains pending further regulatory processes. Local health authorities will determine registration, evaluation, and potential public funding inclusion timelines for patients awaiting the therapy.